Lilly Gets EUA For Antibody Cocktail It Says Might Target Variants

By Kelly Lienhard / February 9, 2021 at 10:42 PM
FDA on Tuesday night (Feb. 9) granted emergency use authorization for a combination of monoclonal antibodies from Eli Lilly, bamlanivimab and etesevimab, to treat patients who experience mild to moderate COVID-19 symptoms and are at risk of severe adverse health effects or hospitalization. Though FDA’s EUA does not say whether the combination therapy could be used for variant strains of the SARS-CoV-2 virus, Lilly says it believes the combination therapy could eventually prove to be beneficial against emerging variants. The...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.